Discover
KNSA
Kiniksa Pharmaceuticals International, plc
62.88
2 x 45.37
2 x 80.24
bid
ask
-
1.07
1.67%
2 @ 04:00 PM
59.20 -3.68 (5.86%)
| Ytd | 52.45% | |
| 1y | 130.86% |
62.60
day range
64.09
26.27
52 week range
64.81
| Open | 63.64 | Prev Close | 63.95 | Low | 62.60 | High | 64.09 | Mkt Cap | 4.84B |
| Vol | 657.01K | Avg Vol | 804.98K | EPS | 0.91 | P/E | 69.10 | Forward P/E | 35.78 |
| Beta | 0.12 | Short Ratio | 5.52 | Inst. Own | 102.58% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 53.39 | 200-d Avg | 44.93 | 1yr Est | 65.13 |
| Income Statement | |||
| Total Revenue | 214.27M | ||
| Revenues (USD) | 214.27M | ||
| Cost of Revenue | 20.80M | ||
| Gross Profit | 193.47M | ||
| Operating Expenses | 164.20M | ||
| Research and Development Expense | 27.48M | ||
| Selling, General and Administrative Expense | 61.15M | ||
| Operating Income | 29.27M | ||
| Income Tax Expense | 10.09M | ||
| Net Income | 22.59M | ||
| Net Income Common Stock | 22.59M | ||
| Net Income Common Stock (USD) | 22.59M | ||
| Consolidated Income | 22.59M | ||
| Earnings per Basic Share | 0.30 | ||
| Earnings per Basic Share (USD) | 0.30 | ||
| Earnings per Diluted Share | 0.27 | ||
| Earning Before Interest & Taxes (EBIT) | 32.68M | ||
| Earning Before Interest & Taxes (USD) | 32.68M | ||
| Weighted Average Shares | 76.52M | ||
| Weighted Average Shares Diluted | 82.41M | ||
| Balance Sheet | |||
| Cash and Equivalents | 189.95M | ||
| Cash and Equivalents (USD) | 189.95M | ||
| Investments | 278.14M | ||
| Investments Current | 278.14M | ||
| Trade and Non-Trade Receivables | 23.22M | ||
| Current Assets | 594.17M | ||
| Property, Plant & Equipment Net | 11.32M | ||
| Total Assets | 825.28M | ||
| Debt Current | 3.17M | ||
| Total Debt | 9.03M | ||
| Current Liabilities | 156.61M | ||
| Debt Non-Current | 5.86M | ||
| Total Liabilities | 219.59M | ||
| Accumulated Retained Earnings (Deficit) | -439.55M | ||
| Accumulated Other Comprehensive Income | -665.00K | ||
| Shareholders Equity | 605.69M | ||
| Shareholders Equity (USD) | 605.69M | ||
| Assets Non-Current | 231.11M | ||
| Total Debt (USD) | 9.03M | ||
| Deferred Revenue | 31.81M | ||
| Goodwill and Intangible Assets | 15.00M | ||
| Inventory | 73.14M | ||
| Liabilities Non-Current | 62.98M | ||
| Trade and Non-Trade Payables | 24.40M | ||
| Tax Assets | 193.63M | ||
| Cash Flow | |||
| Depreciation, Amortization & Accretion | 1.46M | ||
| Net Cash Flow from Financing | 6.07M | ||
| Net Cash Flow / Change in Cash & Cash Equivalents | 24.36M | ||
| Capital Expenditure | -161.00K | ||
| Issuance (Purchase) of Equity Shares | 6.07M | ||
| Net Cash Flow from Investing | -31.92M | ||
| Net Cash Flow - Investment Acquisitions and Disposals | -31.75M | ||
| Net Cash Flow from Operations | 50.20M | ||
| Share Based Compensation | 10.06M | ||